Glaukos Corp(GKOS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GKOS Glaukos Corp

盘后交易 02-03 18:52:17 EST

118.14

+0.67

+0.57%

盘后118.14

+0.000.00%

17:55 EST

最高119.57	最低116.40	成交量50.16万
今开118.52	昨收117.47	日振幅2.70%
总市值67.85亿	流通市值65.45亿	总股本5,743万
成交额5,907万	换手率0.91%	流通股本5,540万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GKOS","market":"US","secType":"STK","nameCN":"Glaukos Corp","latestPrice":118.14,"timestamp":1770152400000,"preClose":117.47,"halted":0,"volume":501592,"hourTrading":{"tag":"盘后","latestPrice":118.14,"preClose":118.14,"latestTime":"17:55 EST","volume":14776,"amount":1745636.64,"timestamp":1770159347108,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.005703583893760123,"floatShares":55401390,"shares":57434740,"eps":-1.544832,"marketStatus":"盘后交易","change":0.67,"latestTime":"02-03 18:52:17 EST","open":118.52,"high":119.5699,"low":116.4,"amount":59070490.494288,"amplitude":0.026985,"askPrice":122.45,"askSize":20,"bidPrice":114.23,"bidSize":91,"shortable":3,"etf":0,"ttmEps":-1.544832,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1770166800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1435204800000,"exchange":"NYSE","adjPreClose":117.47,"preHourTrading":{"tag":"盘前","latestPrice":117.47,"preClose":117.47,"latestTime":"08:20 EST","volume":1,"amount":117.47,"timestamp":1770124842202,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":118.14,"preClose":118.14,"latestTime":"17:55 EST","volume":14776,"amount":1745636.64,"timestamp":1770159347108,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.642893,"impliedVol":0.6803,"impliedVolPercentile":0.7809},"requestUrl":"/m/hq/s/GKOS","defaultTab":"news","newsList":[{"id":"2604795917","title":"Glaukos Corporation盘中异动 股价大涨5.22%报120.46美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604795917","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604795917?lang=zh_cn&edition=full","pubTime":"2026-01-17 00:42","pubTimestamp":1768581779,"startTime":"0","endTime":"0","summary":"北京时间2026年01月17日00时42分，Glaukos Corporation股票出现异动，股价快速上涨5.22%。截至发稿，该股报120.46美元/股，成交量55.43万股，换手率0.97%，振幅5.44%。Glaukos Corporation股票所在的医疗器械行业中，整体跌幅为0.17%。Glaukos Corporation公司简介：Glaukos Corp是一家眼科制药和医疗技术公司，专注于开发用于青光眼、角膜疾病和视网膜疾病治疗的新型、无滴疗法和商业化相关产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011700425997a2264d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011700425997a2264d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0009354923.USD","LU1878469433.USD","GKOS","BK4548","BK4082","LU2065731478.USD"],"gpt_icon":0},{"id":"1162242516","title":"异动解读 | Glaukos重申年度净销售额预期，盘前大跌13.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162242516","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162242516?lang=zh_cn&edition=full","pubTime":"2026-01-14 18:08","pubTimestamp":1768385325,"startTime":"0","endTime":"0","summary":"Glaukos Corp(GKOS)今日盘前股价大跌13.82%，引发市场广泛关注。消息面上，该公司重申了2026年净销售额预期在6亿至6.2亿美元之间，这一举动被市场解读为缺乏增长惊喜，导致投资者抛售股票。尽管公司初步预计2025年全年净销售额为5.07亿美元，高于此前预期的4.9亿至4.95亿美元，但市场更关注的是2026年的预期，重申相同目标可能意味着公司对未来增长的保守态度。Glaukos将于2月17日公布第四季度和全年业绩报告，投资者将密切关注其业绩表现及未来指引。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GKOS"],"gpt_icon":0},{"id":"1116649649","title":"异动解读 | Glaukos重申2026年营收预期后夜盘大跌12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1116649649","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116649649?lang=zh_cn&edition=full","pubTime":"2026-01-14 16:36","pubTimestamp":1768379814,"startTime":"0","endTime":"0","summary":"眼科医疗技术公司Glaukos Corp(GKOS)今日夜盘股价大跌12%，引发市场关注。消息面上，该公司在公布2025年第四季度及全年初步未经审计净销售额后，重申了2026年净销售额预期在6亿至6.2亿美元之间。这一举动被市场解读为缺乏增长惊喜，导致投资者抛售股票。数据显示，Glaukos初步预计2025年全年净销售额为5.07亿美元，高于此前预期的4.9亿至4.95亿美元。然而，市场更关注的是2026年的预期，重申相同目标可能意味着公司对未来增长的保守态度。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GKOS"],"gpt_icon":0},{"id":"1134812503","title":"Glaukos公布2025年第四季度及全年初步未经审计净销售额 并重申2026年营收指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1134812503","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134812503?lang=zh_cn&edition=full","pubTime":"2026-01-14 05:06","pubTimestamp":1768338379,"startTime":"0","endTime":"0","summary":"眼科医疗技术公司Glaukos Corp近日披露了2025财年第四季度及全年的初步净销售额数据，该数据尚未经过审计机构审核。与此同时，这家专注于创新疗法研发的企业再次确认了其对2026财年的营业收入预期目标。\n此次公布的初步业绩数据显示，公司在过去一年保持了稳健的业务发展态势。尽管面临市场竞争加剧等挑战，Glaukos通过持续推动产品创新和市场拓展，实现了预期的业绩表现。\n值得关注的是，管理层在公布初步销售数据的同时，明确表达了对未来发展的信心，重申了2026财年的营收指引。这一举措向市场传递出公司对核心业务增长潜力的积极预期，也反映出其战略规划的前瞻性和可持续性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","BK4548","BK4082","GKOS","LU2065731478.USD","IE0009354923.USD"],"gpt_icon":0},{"id":"1157275147","title":"异动解读 | 业绩超预期，Glaukos盘前大涨20.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157275147","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157275147?lang=zh_cn&edition=full","pubTime":"2025-10-30 19:44","pubTimestamp":1761824664,"startTime":"0","endTime":"0","summary":"眼科医疗技术公司Glaukos Corp周四盘前股价大涨20.90%，引发投资者广泛关注。根据公司公布的财报，Glaukos第三季度销售额达到1.335亿美元，远超市场分析机构IBES预期的1.225亿美元。Glaukos的这份优异财报显示，公司在眼科医疗技术领域的市场地位不断巩固，产品需求旺盛。高于预期的销售额和毛利率大大提振了投资者信心，推动股价在盘前交易中大幅上涨。这一业绩表现也凸显了Glaukos在眼科医疗技术市场的竞争力和增长潜力，有望为公司未来的持续发展奠定坚实基础。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GKOS"],"gpt_icon":0},{"id":"1125583389","title":"异动解读 | 业绩超预期，Glaukos夜盘大涨18.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=1125583389","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125583389?lang=zh_cn&edition=full","pubTime":"2025-10-30 08:41","pubTimestamp":1761784860,"startTime":"0","endTime":"0","summary":"眼科医疗技术公司Glaukos Corp周三夜盘交易中股价大幅上涨18.23%，引发投资者广泛关注。这一显著涨幅主要源于公司发布的亮眼第三季度财报。根据公司公布的财报，Glaukos第三季度销售额达到1.335亿美元，远超市场分析机构IBES预期的1.225亿美元。Glaukos的这份优异财报显示，公司在眼科医疗技术领域的市场地位不断巩固，产品需求旺盛。这一业绩表现也凸显了Glaukos在眼科医疗技术市场的竞争力和增长潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GKOS"],"gpt_icon":0},{"id":"1139565949","title":"异动解读 | 业绩超预期，Glaukos盘后大涨14.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139565949","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139565949?lang=zh_cn&edition=full","pubTime":"2025-10-30 04:33","pubTimestamp":1761769981,"startTime":"0","endTime":"0","summary":"周三盘后交易中，眼科医疗技术公司Glaukos Corp股价大幅上涨14.15%，引发投资者广泛关注。Glaukos公布的第三季度销售额达到1.335亿美元，远超市场分析机构IBES预期的1.225亿美元。此外，公司第三季度调整后毛利率高达84%，展现出强劲的盈利能力。Glaukos的这份优异财报显示，公司在眼科医疗技术领域的市场地位不断巩固，产品需求旺盛。高于预期的销售额和毛利率不仅反映了公司的业务增长势头，也表明其在成本控制和运营效率方面取得了显著进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GKOS"],"gpt_icon":0},{"id":"1153490464","title":"Glaukos第三季度销售额1.335亿美元，超出IBES预期的1.225亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153490464","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153490464?lang=zh_cn&edition=full","pubTime":"2025-10-30 04:25","pubTimestamp":1761769527,"startTime":"0","endTime":"0","summary":"10月29日 - Glaukos第三季度调整后毛利率达到84%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","LU1878469433.USD","LU2065731478.USD","IE0009354923.USD","BK4548","GKOS"],"gpt_icon":0},{"id":"1139866422","title":"Glaukos Corp：富国银行将评级从持平上调至增持；目标价由92美元上调至120美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1139866422","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139866422?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:02","pubTimestamp":1761562948,"startTime":"0","endTime":"0","summary":"Glaukos Corp：富国银行将评级从持平上调至增持；目标价由92美元上调至120美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","GKOS","LU2065731478.USD","BK4548","IE0009354923.USD","BK4082"],"gpt_icon":0},{"id":"2567189245","title":"Glaukos Corporation盘中异动 急速跳水5.09%报83.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2567189245","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567189245?lang=zh_cn&edition=full","pubTime":"2025-09-13 00:42","pubTimestamp":1757695345,"startTime":"0","endTime":"0","summary":"北京时间2025年09月13日00时42分，Glaukos Corporation股票出现异动，股价快速跳水5.09%。截至发稿，该股报83.02美元/股，成交量22.8241万股，换手率0.40%，振幅4.97%。Glaukos Corporation股票所在的医疗器械行业中，整体跌幅为0.76%。Glaukos Corporation公司简介：Glaukos Corp是一家眼科制药和医疗技术公司，专注于开发用于青光眼、角膜疾病和视网膜疾病治疗的新型、无滴疗法和商业化相关产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250913004225a4c31225&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250913004225a4c31225&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1878469433.USD","BK4548","IE0009354923.USD","GKOS","LU2065731478.USD","BK4082"],"gpt_icon":0},{"id":"2556784808","title":"Glaukos Corporation2025财年第二财季实现净利润-19.66百万美元，同比增加61.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556784808","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556784808?lang=zh_cn&edition=full","pubTime":"2025-08-04 00:01","pubTimestamp":1754236867,"startTime":"0","endTime":"0","summary":"8月4日，Glaukos Corporation公布财报，公告显示公司2025财年第二财季净利润为-19.66百万美元，同比增加61.11%；其中营业收入为1.24亿美元，同比增加29.59%，每股基本收益为-0.34美元。从资产负债表来看，Glaukos Corporation总负债2.22亿美元，其中短期债务--，资产负债比为4.45，流动比率为0.06。机构评级：截至2025年8月4日，当前有13家机构对Glaukos Corporation目标价做出预测，其中目标均价为122.46美元，其中最低目标价为72.00美元，最高目标价为165.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804000231a472bcce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804000231a472bcce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GKOS"],"gpt_icon":0},{"id":"2518322289","title":"Glaukos Corporation跌4.08% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2518322289","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518322289?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:32","pubTimestamp":1741613579,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时32分，Glaukos Corporation股票出现波动，股价急速跳水4.08%。截至发稿，该股报99.94美元/股，成交量8598股，换手率0.02%，振幅1.40%。Glaukos Corporation股票所在的医疗器械行业中，整体跌幅为0.62%。Glaukos Corporation公司简介：Glaukos Corp是一家眼科制药和医疗技术公司，专注于开发用于青光眼、角膜疾病和视网膜疾病治疗的新型、无滴疗法和商业化相关产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213300a26a2520&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213300a26a2520&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2065731478.USD","GKOS","IE0009354923.USD","LU1878469433.USD","BK4548","BK4082"],"gpt_icon":0},{"id":"2517319455","title":"Glaukos Corporation盘中异动 下午盘急速下跌5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517319455","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517319455?lang=zh_cn&edition=full","pubTime":"2025-03-07 02:26","pubTimestamp":1741285610,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日02时26分，Glaukos Corporation股票出现波动，股价快速跳水5.14%。截至发稿，该股报106.36美元/股，成交量29.6086万股，换手率0.52%，振幅3.26%。Glaukos Corporation股票所在的医疗器械行业中，整体跌幅为2.00%。Glaukos Corporation公司简介：Glaukos Corp是一家眼科制药和医疗技术公司，专注于开发用于青光眼、角膜疾病和视网膜疾病治疗的新型、无滴疗法和商业化相关产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307022651963c7667&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307022651963c7667&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0009354923.USD","LU2065731478.USD","GKOS","BK4548","LU1878469433.USD","BK4082"],"gpt_icon":0},{"id":"2516373576","title":"Glaukos Corporation盘中异动 早盘急速下跌5.18%报113.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516373576","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516373576?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:05","pubTimestamp":1741014342,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时05分，Glaukos Corporation股票出现波动，股价大幅下挫5.18%。截至发稿，该股报113.80美元/股，成交量10.7329万股，换手率0.19%，振幅4.82%。Glaukos Corporation股票所在的医疗器械行业中，整体涨幅为0.59%。Glaukos Corporation公司简介：Glaukos Corp是一家眼科医疗技术公司，从事开发和商业化用于治疗青光眼的产品和程序。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230542989a199d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230542989a199d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0009354923.USD","LU1878469433.USD","BK4082","GKOS","LU2065731478.USD","BK4548"],"gpt_icon":0},{"id":"2514015888","title":"Glaukos Corporation盘中异动 早盘股价大跌5.20%报117.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514015888","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514015888?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:11","pubTimestamp":1740496279,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时11分，Glaukos Corporation股票出现异动，股价急速下跌5.20%。截至发稿，该股报117.78美元/股，成交量19.1002万股，换手率0.34%，振幅5.88%。Glaukos Corporation股票所在的医疗器械行业中，整体跌幅为0.41%。Glaukos Corporation公司简介：Glaukos Corp是一家眼科医疗技术公司，从事开发和商业化用于治疗青光眼的产品和程序。它提供iStent，一种微型旁路支架，可与白内障手术配合插入，以降低成年人轻度至中度开角型青光眼患者的眼内压。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225231120962ffbaa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225231120962ffbaa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GKOS","LU2065731478.USD","BK4548","LU1878469433.USD","IE0009354923.USD","BK4082"],"gpt_icon":0},{"id":"2513375613","title":"Glaukos Corporation2024财年实现净利润-1.46亿美元，同比减少8.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513375613","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513375613?lang=zh_cn&edition=full","pubTime":"2025-02-24 00:01","pubTimestamp":1740326467,"startTime":"0","endTime":"0","summary":"2月24日，Glaukos Corporation公布财报，公告显示公司2024财年净利润为-1.46亿美元，同比减少8.15%；其中营业收入为3.83亿美元，同比增加21.59%，每股基本收益为-2.77美元。从资产负债表来看，Glaukos Corporation总负债2.08亿美元，其中短期债务--，资产负债比为4.69，流动比率为0.06。机构评级：截至2025年2月24日，当前有13家机构对Glaukos Corporation目标价做出预测，其中目标均价为168.62美元，其中最低目标价为120.00美元，最高目标价为200.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000140abd9c7e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000140abd9c7e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GKOS"],"gpt_icon":0},{"id":"1174826046","title":"异动解读 | 医疗器械公司Glaukos第四季度亏损扩大 股价大跌13.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174826046","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174826046?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:37","pubTimestamp":1740148650,"startTime":"0","endTime":"0","summary":"医疗技术公司Glaukos(GKOS)今日盘中大跌13.2%,引发市场广泛关注。\n\n该公司昨日公布了2024年第四季度财报,数据显示当季净亏损达到2220万美元,大幅超出市场预期的2080万美元亏损。尽管营收达到1.055亿美元高于预期,但亏损扩大的情况仍令投资者信心受挫。\n\n值得一提的是,Glaukos的主要产品iStent inject W是一种用于治疗青光眼的创新医疗器械,针对这种常见但损害视神经的眼病。公司的这一核心业务前景广阔,但本季度的财报业绩不佳或许给市场带来一些负面影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GKOS"],"gpt_icon":0},{"id":"2513296561","title":"Glaukos Corporation盘中异动 急速下挫12.32%报137.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513296561","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513296561?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:32","pubTimestamp":1740148334,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时32分，Glaukos Corporation股票出现波动，股价快速下挫12.32%。截至发稿，该股报137.97美元/股，成交量13.5999万股，换手率0.24%，振幅3.79%。Glaukos Corporation股票所在的医疗器械行业中，整体跌幅为0.36%。Glaukos Corporation公司简介：Glaukos Corp是一家眼科医疗技术公司，从事开发和商业化用于治疗青光眼的产品和程序。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223214abd7afc4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223214abd7afc4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1878469433.USD","GKOS","LU2065731478.USD","BK4548","IE0009354923.USD","BK4082"],"gpt_icon":0},{"id":"1126707519","title":"异动解读 | 医疗技术公司Glaukos第四季度亏损扩大,股价盘前大跌11.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=1126707519","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126707519?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:10","pubTimestamp":1740147030,"startTime":"0","endTime":"0","summary":"医疗技术公司Glaukos(GKOS)股价今日盘前大跌11.67%,引发市场广泛关注。\n\nGlaukos公司昨日发布了第四季度财报,数据显示该公司第四季度净亏损扩大至2220万美元,远超市场预期的2080万美元亏损。虽然营收达到1.055亿美元高于市场预期,但仍未能令投资者信心完全恢复。\n\n值得一提的是,Glaukos的主要产品iStent inject W是一种用于治疗青光眼的创新医疗器械,针对一种损害视神经的严重眼病。公司业务发展前景一直备受市场关注,但近期财务数据不佳或许给投资者带来一些负面影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GKOS"],"gpt_icon":0},{"id":"2513267826","title":"Needham：维持Glaukos(GKOS.US)评级，由买入调整至买入评级, 目标价由149.00美元调整至176.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513267826","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513267826?lang=zh_cn&edition=full","pubTime":"2025-02-21 20:51","pubTimestamp":1740142319,"startTime":"0","endTime":"0","summary":"Needham：维持Glaukos(GKOS.US)评级，由买入调整至买入评级, 目标价由149.00美元调整至176.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/21205148319260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["GKOS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.glaukos.com","stockEarnings":[{"period":"1week","weight":-0.0547},{"period":"1month","weight":0.061},{"period":"3month","weight":0.3667},{"period":"6month","weight":0.3275},{"period":"1year","weight":-0.2491},{"period":"ytd","weight":0.0404}],"compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0179},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.099},{"period":"1year","weight":0.1555},{"period":"ytd","weight":0.0198}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Glaukos Corporation于1998年7月14日在特拉华州注册成立。该公司是一家眼科制药和医疗技术公司，专注于开发新型无滴剂疗法，并将相关产品商业化，用于治疗青光眼、角膜疾病和视网膜疾病。他们首先开发了微创青光眼手术（MIGS）作为传统青光眼治疗模式的替代方案，并于2012年推出了他们的第一台MIGS设备。他们还提供商业化的专有生物激活药物疗法，用于治疗罕见的角膜疾病圆锥角膜，该疗法于2016年获得美国食品和药物管理局（FDA）的批准。他们正在开发一系列平台，以支持正在进行的制药和医疗器械创新。","yearOnYearQuotes":[{"month":1,"riseRate":0.909091,"avgChangeRate":0.08374},{"month":2,"riseRate":0.545455,"avgChangeRate":-0.0078},{"month":3,"riseRate":0.6,"avgChangeRate":-0.022683},{"month":4,"riseRate":0.5,"avgChangeRate":0.010953},{"month":5,"riseRate":0.6,"avgChangeRate":0.024636},{"month":6,"riseRate":0.9,"avgChangeRate":0.110675},{"month":7,"riseRate":0.636364,"avgChangeRate":0.018448},{"month":8,"riseRate":0.454545,"avgChangeRate":0.049318},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.031897},{"month":10,"riseRate":0.545455,"avgChangeRate":-0.015452},{"month":11,"riseRate":0.545455,"avgChangeRate":0.030479},{"month":12,"riseRate":0.545455,"avgChangeRate":0.013516}],"exchange":"NYSE","name":"Glaukos Corp","nameEN":"Glaukos"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Glaukos Corp(GKOS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Glaukos Corp(GKOS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Glaukos Corp,GKOS,Glaukos Corp股票,Glaukos Corp股票老虎,Glaukos Corp股票老虎国际,Glaukos Corp行情,Glaukos Corp股票行情,Glaukos Corp股价,Glaukos Corp股市,Glaukos Corp股票价格,Glaukos Corp股票交易,Glaukos Corp股票购买,Glaukos Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Glaukos Corp(GKOS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Glaukos Corp(GKOS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}